Single-use Biomanufacturing Industry boosting the growth Worldwide

Single use bioprocessing market was valued at USD 19.36 billion in 2021 with a CAGR of 16.6% during 2022-2030. Single-use bioreactor market and Single-use assemblies market are also growing at a CAGR of 17.6% and 18.57% respectively. 


Single-use Biomanufacturing Industry | Forecast 2030

Single-use Biomanufacturing Industry Data Book - Single-Use Bioprocessing, Bioreactor, Assemblies Filtration Assemblies Market Size, Share, Trends Analysis, And Segment Forecasts, 2022 – 2030

Single use bioprocessing market was valued at USD 19.36 billion in 2021 with a CAGR of 16.6% during 2022-2030. Single-use bioreactor market and Single-use assemblies market are also growing at a CAGR of 17.6% and 18.57% respectively. 

Access the Global Single-use Biomanufacturing Industry Data Book, 2022 to 2030, compiled with details like market sizing forecasts insights, market dynamics trends, opportunity assessment, regulatory technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies

Single-use Bioprocessing Market Growth Trends

The global single-use bioprocessing market size is projected to reach USD 80,129 million by 2030, registering a compound annual growth rate (CAGR) of 16.24% over the forecast period, according to a new report by Grand View Research, Inc. The demand for single-use bioprocessing offerings is driven by the commercial advantages offered, including a reduction in costs and time required for bioprocessing operations. Originally used for monoclonal antibody production, single-use technologies are also gaining traction for cell and gene therapy manufacturing. As a result, broadening the scope of applications in biomanufacturing operations is likely to drive industry growth.

Furthermore, strategic initiatives from key players are expanding the industry's growth prospects. For instance, in July 2021, Cytiva and Pall Corp. announced investment plans for capacity expansion over two years. Among other key products, more than USD 300 million were invested in single-use technologies, such as bioreactor bags for cell expansion, used to make personalized therapies and syringe filters for scientific research. Similarly, the growing adoption of single-use equipment for in-house and contract manufacturing has opened new avenues for the flow of investments in this space. The industry is witnessing significant advancements in several product portfolios, including disposable probes and sensors, stirring systems, bioreactor designs, and filtration technologies, which are expected to contribute to strong revenue growth.

The benefits offered by single-use bioprocessing systems have enabled biopharmaceutical manufacturers to offer their products faster to the market by introducing multi-product facilities, entering into partnerships, or outsourcing pipeline products for contract development and manufacturing. For instance, in January 2021, Sartorius AG partnered with RoosterBio, a leading supplier of human Mesenchymal Stem/Stromal Cells (hMSC). This collaboration aimed at advancing cell gene therapy manufacturing by leveraging the single-use manufacturing technologies from Sartorius AG. The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry.

Key biopharmaceutical players can leverage the opportunity by expanding their COVID-19-related product offerings by scaling up their production facilities with the implementation of single-use bioprocessing equipment. A significant number of biopharmaceutical companies are actively involved in the development and production of COVID-19 vaccines. These programs are majorly based on single-use technologies as these systems are flexible, cost-effective, and reduce the risk of cross-contamination. Such an ongoing and continuous increase in the adoption of bioprocessing systems due to the COVID-19 pandemic is anticipated to drive industry growth.

Single-use Bioreactors Market Growth Trends

The global single-use bioreactors market size is expected to reach USD 12.06 billion by 2030, registering a CAGR of 17.19% from 2023 to 2030, according to a new report by Grand View Research, Inc. Owing to the rising demand for biopharmaceuticals, coupled with increasing investments in single-use technologies, the market for single-use bioreactors is expected to witness significant growth throughout the forecast period.

Furthermore, the COVID-19 outbreak has positively impacted the market for SUBs. The race to create an effective vaccine against the SARS-CoV-2 virus is being undertaken by numerous biopharmaceutical firms. As a result, the need for single-use bioreactors has drastically increased. For instance, in October 2020, ABEC supplied six 4,000 L single-use bioreactors to the Serum Institute of India, for the production of COVID-19 vaccines on a large scale at a reasonable cost.

The value of the product, the time required for product development and production, in addition to the criticality of the phase are now influencing the industry's propensity to employ single-use bioreactors. In addition, the medical industry has a significant demand for these single-use bioreactors. As a result, pharmaceutical companies use these reactors to make medicines without having to compromise on their quality.

The flexibility of using single-use bioreactors is one of their main benefits. The growing trend toward multi-drug facilities necessitates the manufacture of various medications utilizing the same facility, in the shortest amount of time, and for the least amount of money. Thus, it will increase the demand for single-use bioreactors and further fuel market growth.

Additionally, the market for SUBs is anticipated to increase quickly because of considerable prospects from emerging countries, the demand for customized medicine, and an anticipated rise in bio-similar production in the U.S. For instance, around USD 110 billion worth of biologics were anticipated to lose their patent protection by 2020. The demand for biosimilars is therefore expected to rise in the coming years as a result of mounting pressure to lower healthcare costs and regulatory certainty about biosimilars, further driving the market growth.

Order your copy of the Free Sample of “Single-use Biomanufacturing Industry Data Book - Single-Use Bioprocessing, Bioreactor, Assemblies Filtration Assemblies Market Size, Share, Trends Analysis, And Segment Forecasts, 2022 - 2030, 2022 - 2030” Data Book, published by Grand View Research


Single-use Assemblies Market Growth Trends

The global single-use assemblies market size is expected to reach USD 39.96 billion by 2030, registering a CAGR of 18.60% during the forecast period, according to a new report by Grand View Research, Inc. Life science companies are eager to avoid the cost and time of cleaning needed with stainless steel. The augmented expansion of the international biotech industries has offered a growth environment, in which novel, disposable technologies are becoming more significant. As pharmaceutical companies, distributors, CDMOs, and manufacturers converge around the benefits of single-use assemblies, the industry will grow at a faster pace during the forecast period. From therapies for rare diseases to cancer research, the impact of single-use technology in accelerating cutting-edge research into these conditions is set to grow, thereby propelling industry growth.

In addition, the growing biologics market will further offer lucrative opportunities during the study period. Eradicating the risk of contamination is the major challenge faced by biopharmaceutical manufacturers, which currently involves high-level monitoring of critical manufacturing solutions. Single-use assemblies support manufacturers in overcoming this difficulty by eliminating or reducing the necessity for sterilization between the batches, thereby filtering the operational capability. SUTs are considered one of the important areas of growth among biomanufacturing companies, as several biopharmaceutical companies are venturing into disposable assembly offerings for the production of all sorts of biopharmaceuticals.

Moreover, SUTs are now being heavily adopted for the clinical manufacturing of biopharmaceuticals and have become more conventional within commercial manufacturing facilities. SUTs permit biologics manufacturers to reduce the facilities' footprint by almost 20% due to the need for utilities, which generate steam, water, and clean-in-place solutions. Furthermore, as per the research by BioProcess International, the engineers estimated that the capital expenditure for the single-use facility is 25-45% less than for a facility established on stainless-steel equipment. Similarly, they also estimated that single-use facilities need half the energy and water during operations and can be built in 18 months. Whereas the stainless-steel facility takes three years. Owing to such advantages, the adoption of single-use assemblies is increasing, thereby driving industry growth.

Single-use Filtration Assemblies Market
Growth Trends

The global single-use filtration assemblies market size is expected to reach USD 7.0 billion by 2026 and is projected to exhibit a CAGR of 11.2%, according to a new report by Grand View Research, Inc. The market is significantly driven by the expansion of the biotherapeutics industry and budget constraints faced by small to medium-sized end users. At present, single-use technology has become a cost-saving strategy for contract manufacturers, thus most of the CMOs are inclined toward the use of disposable filter cartridges and tubing systems.

The robustness of venture capital investments is one of the important supportive factors for market growth. Increase in availability of venture funds for life science fields is anticipated to spur the adoption of disposable filtering units among research laboratories and biopharmaceutical developers.

Companies are engaged in revolutionizing single-use filtration assemblies using pre-assembled devices, which can reduce the usage of sterile connection and tubing. In addition, it reduces integrity testing time. Such solutions are being employed even for large-scale filtering processes.

Competitive Landscape

Key players operating in the single-use biomanufacturing industry are –

  • Thermo Fisher Scientific, Inc.;
  • Sartorius AG;
  • Corning, Inc.;
  • Eppendorf AG;
  • PBS Biotech, Inc.;
  • Avantor, Inc.;
  • Entegris, Inc.;
  • Kuhner AG;
  • Danaher Corporation;
  • Merck KGaA.


Grand View Research’s life science microscopes Industry data book is a collection of market sizing information forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.


Check out more Industry Data Books, published by Grand View Research